225 related articles for article (PubMed ID: 38302471)
1. Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer.
Li Y; Wang B; Yang W; Ma F; Zou J; Li K; Tan S; Feng J; Wang Y; Qin Z; Chen Z; Ding C
Nat Commun; 2024 Feb; 15(1):980. PubMed ID: 38302471
[TBL] [Abstract][Full Text] [Related]
2. Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies.
Li Y; Wang B; Ma F; Jiang D; Wang Y; Li K; Tan S; Feng J; Wang Y; Qin Z; Xu G; Tian S; Zhang X; Xu C; Wu J; Xu J; Hou Y; Ding C
Cell Rep Med; 2023 Dec; 4(12):101311. PubMed ID: 38086380
[TBL] [Abstract][Full Text] [Related]
3. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.
Katsila T; Juliachs M; Gregori J; Macarulla T; Villarreal L; Bardelli A; Torrance C; Elez E; Tabernero J; Villanueva J
Clin Cancer Res; 2014 Dec; 20(24):6346-56. PubMed ID: 25324142
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.
de Wit M; Kant H; Piersma SR; Pham TV; Mongera S; van Berkel MP; Boven E; Pontén F; Meijer GA; Jimenez CR; Fijneman RJ
J Proteomics; 2014 Mar; 99():26-39. PubMed ID: 24418523
[TBL] [Abstract][Full Text] [Related]
5. ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer.
Hong HJ; Shao Y; Zhang S; Yang G; Jia H; Yang X; Huang L; Li S; Aikemu B; Zhang L; Ma J; Zang L; Sun J; Zheng M
Acta Biochim Biophys Sin (Shanghai); 2022 Sep; 54(11):1671-1683. PubMed ID: 36111743
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
7. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
[TBL] [Abstract][Full Text] [Related]
9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
10. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
11. Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.
Yonesaka K; Takegawa N; Satoh T; Ueda H; Yoshida T; Takeda M; Shimizu T; Chiba Y; Okamoto I; Nishio K; Tamura T; Nakagawa K
PLoS One; 2015; 10(11):e0143132. PubMed ID: 26569500
[TBL] [Abstract][Full Text] [Related]
12. Aberrant up-regulation of iNOS/NO system is correlated with an increased abundance of Foxp3
Benkhelifa S; Rafa H; Belhadef S; Ait-Kaci H; Medjeber O; Belkhelfa M; Hetit S; Ait-Younes S; De Launoit Y; Moralès O; Mahfouf H; Delhem N; Touil-Boukoffa C
Inflammopharmacology; 2019 Aug; 27(4):685-700. PubMed ID: 30680650
[TBL] [Abstract][Full Text] [Related]
13. Probing the colorectal cancer proteome for biomarkers: Current status and perspectives.
Lee PY; Chin SF; Low TY; Jamal R
J Proteomics; 2018 Sep; 187():93-105. PubMed ID: 29953962
[TBL] [Abstract][Full Text] [Related]
14. Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family.
Peltier J; Roperch JP; Audebert S; Borg JP; Camoin L
J Proteomics; 2016 Oct; 148():139-48. PubMed ID: 27492143
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
[TBL] [Abstract][Full Text] [Related]
16. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
[TBL] [Abstract][Full Text] [Related]
17. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer.
Fijneman RJ; de Wit M; Pourghiasian M; Piersma SR; Pham TV; Warmoes MO; Lavaei M; Piso C; Smit F; Delis-van Diemen PM; van Turenhout ST; Terhaar sive Droste JS; Mulder CJ; Blankenstein MA; Robanus-Maandag EC; Smits R; Fodde R; van Hinsbergh VW; Meijer GA; Jimenez CR
Clin Cancer Res; 2012 May; 18(9):2613-24. PubMed ID: 22351690
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
[TBL] [Abstract][Full Text] [Related]
19. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
20. An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer.
Han CL; Chen JS; Chan EC; Wu CP; Yu KH; Chen KT; Tsou CC; Tsai CF; Chien CW; Kuo YB; Lin PY; Yu JS; Hsueh C; Chen MC; Chan CC; Chang YS; Chen YJ
Mol Cell Proteomics; 2011 Apr; 10(4):M110.003087. PubMed ID: 21209152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
